Not covered is not the same as unproven

INSURANCE AND ORTHOBIOLOGICS

Almost every private insurer, and Medicare, will not pay for PRP. That is the fact, and it is the only one your plan letter is actually reporting. It is a decision about what a plan funds — not a finding about whether the treatment works, and not a description of the evidence, which is now considerable.

What the label actually means

A non-coverage decision is a budgeting decision, not a scientific verdict. It means your insurer weighed the published evidence against the cost of paying for this across everyone they cover, and declined. It does not mean the treatment is unproven. It does not mean it is experimental. It does not mean it is unsafe.

The blind spot in the trial literature

Trials of PRP tend to enroll a narrow group of people: fairly healthy, no metabolic problems, one bad joint. The rules for who may join routinely shut out anyone with diabetes, significant obesity, inflammatory disease, or more than one painful site.

Those rules make sense for the study and distort the picture at the same time. The people they shut out are a large share of the patients who actually walk in with worn tendons and arthritis. Insulin resistance and long-running inflammation are part of why their tissue stopped healing in the first place. So the research gets built on the patients least like you. It produces a modest average result, insurers read that modest average, and the label follows.

This cuts both ways, and we will not pretend otherwise: a thin evidence base is a real reason for caution. It is simply not the same thing as evidence of no effect, and the distinction matters when you are deciding what to do about a shoulder that has hurt for two years.

What this practice will and will not tell you

We will tell you what we think your odds are, based on your tissue, your imaging and your metabolic health. We will tell you when we think PRP is a poor bet. We do not publish prices on this website, and we do not bill insurance at all — you will know what a course of treatment costs before any blood is drawn, instead of finding out from a statement later.

Call and ask. You will get a straight answer about cost and about likelihood from someone who can see your case.

What a coverage decision is actually deciding

A coverage decision answers one question. Should this plan pay for this service for everyone it covers, given the published evidence and the cost? It is a budgeting call about a whole population.

It does not answer whether the treatment is safe, whether it works for one particular person, or whether a doctor thinks it is reasonable. Plenty of things insurers refuse to cover are sensible. Plenty of things they do cover rest on weaker evidence than PRP. Keyhole surgery to trim a worn meniscus was covered for years, then lost to fake surgery in trials.

Who gets excluded from the trials, specifically

Typical exclusion criteria in PRP trials, and roughly who they remove:

• Diabetes. Commonly excluded, and present in a large share of patients with worn tendons.
• A BMI above some cutoff, often 30 or 35.
• Inflammatory arthritis or autoimmune disease
• More than one painful site. Trials want one clean joint.
• A recent injection, often within some months. That rules out most people who have been treated the usual way for years.
• Age limits, in a disease of aging tissue.

Each rule can be defended on its own. Together they build a study group that is younger, leaner, healthier and simpler than the people who actually walk in. They also remove exactly the patients whose tissue is failing for metabolic reasons, and those are a large share of this clinic.

Why that cuts both ways

It is tempting to conclude that the trials undersell the treatment and that your case is different. That is possible. It is not established.

The excluded patients might do better than the trials suggest, if the metabolic driver gets treated alongside the joint. They might just as easily do worse. Sugar-damaged collagen and a steady inflammatory load are exactly the conditions in which a repair fails. Both are plausible, and the data does not settle it. Any clinic that tells you confidently the trials understate your odds is guessing in the direction that suits them.

The honest conclusion is narrower. The published average describes people unlike you. So your decision has to rest on your own tissue, your stage and your general health, more than on the headline number. That is an argument for a careful assessment, not for optimism.

What we will not do

• Imply that we bill insurance or pursue coverage. We do neither.
• Bill a PRP injection under a code that describes a different service.
• Publish a price on this website or quote one without seeing your case.
• Suggest that we can get a payer to cover this. We cannot, and we do not try.

Call and ask about your own situation and you will get a direct answer.

Related reading

• Paying for treatment
• What a medical lien is
• Why the trials disagree
• Am I a candidate?
• How PRP works
• Information for referring physicians
• Contact

How the classification might change

Coverage determinations do move, and it is reasonable to ask what would move this one.

What is needed is not just more trials but better ones. The preparations have to be described well enough that another lab can reproduce them. The comparisons need enough patients, and a real injected control. Follow-up has to run past a year. And the trials have to enroll the patients they now shut out. Some of that work is underway. None of it changes anything for someone deciding this month.

Workers’ compensation is already a partial exception. In some states it is decided case by case, and it does sometimes succeed, because that payer is weighing your time off work rather than a blanket policy.

What the cost conversation should actually cover

If you are weighing the money, the useful comparison is not one injection against another. It is a full course of treatment and rehabilitation against what you would otherwise spend. That is rarely nothing.

• Repeat cortisone shots, which are covered, and which each last a shorter time in a tissue that is quietly getting worse
• Ongoing physical therapy copays over months or years
• Over-the-counter painkillers, braces, orthotics and the rest of it
• Time off work. For hourly workers that is the biggest number on this list, and it never comes up in a clinical discussion.
• The eventual operation, its recovery, and the time that costs

None of that makes PRP cheap or makes it right for you. It makes the comparison honest.

If cost is the deciding factor

Say so plainly. Nobody here will treat it as an awkward subject. There are cheaper things on this site that are genuinely reasonable for some problems. Prolotherapy has real randomized evidence in knee arthritis and costs far less. And for many tendon problems, a properly supervised exercise program has the best evidence of anything discussed here, and costs less again.

A clinic that only ever recommends its most expensive option is not giving you advice. If the honest answer for your case is that the money is better spent elsewhere, that is what you will be told.

PAYING FOR IT

The determination that says no is the one that unlocks pre-tax dollars

Two different bodies are answering two different questions about the same treatment. Almost nobody explains that they are separate questions.

Your insurer asks one thing. Should this plan pay for this service for everyone it covers, given the published evidence and the cost? For platelet-rich plasma the answer is no.

The tax code asks something else. Was this money paid for medical care — to diagnose, cure, ease, treat or prevent a disease? That is the definition in Internal Revenue Code section 213(d). It says nothing about whether an insurer agreed to pay.

Why non-coverage is the qualifying condition, not the disqualifier

This is the part that surprises people. IRS Publication 969 defines qualified medical expenses for a health savings account as amounts paid for medical care under section 213(d), “but only to the extent the amounts are not compensated for by insurance or otherwise.”

Read that clause again. A cost your plan already paid is not a qualified HSA expense. You cannot use pre-tax dollars to pay yourself back for something the insurer covered. The bill nobody else paid is exactly the one these accounts exist for.

So the denial and the pre-tax question are not two obstacles. The first one is what puts you squarely inside the second.

The three accounts, and how they differ

• HSA — health savings account. Yours, portable, rolls over, requires a high-deductible health plan to contribute. Distributions for qualified medical expenses are tax-free.
• FSA — flexible spending arrangement. Your employer sets it up. You generally use it or lose it within the plan year. It pays you back for qualified costs run up while you were covered.
• HRA — health reimbursement arrangement. Your employer funds it and writes the rules, within the limits the tax code sets. It pays you back for qualified medical costs.

All three run on the same section 213(d) definition of medical care. They differ in who owns the money, what happens to it at year end, and who writes the plan rules. The plan rules are where your own answer actually gets decided.

Where this does not apply, stated plainly

• Cosmetic use does not qualify. Publication 502 is explicit. Anything aimed at appearance, that does not meaningfully improve how the body works or treat a disease, is excluded. PRP for hair or for looks is a different transaction from PRP for an arthritic knee, whatever the syringe looks like.
• You cannot double-dip. If any part of the cost is reimbursed by insurance or another source, that part is not a qualified expense.
• Getting it wrong is expensive. Money you take out for something that does not qualify is taxable, plus an extra 20 percent tax. There are exceptions after age 65, and for disability or death. That penalty is why you ask your plan administrator instead of assuming.
• Your administrator may want paperwork. Some require a letter of medical necessity before releasing funds. We will write one describing the diagnosis and our reasoning. We cannot make your plan accept it.

What we do and do not do here

We give you an itemized receipt with the diagnosis, the service and the date. That is the document any administrator will ask for. We write a letter of medical necessity when one is wanted. And we tell you honestly whether we think the treatment will help you. That is a separate question from how you pay for it, and the more important one.

We are not tax advisers and this is not tax advice. Whether you qualify depends on your own plan documents and your own situation. Check with your plan administrator, and with a tax professional if the amount matters to you. Anyone in a clinic who tells you flatly that PRP is HSA-eligible is answering a question they are not in a position to answer.

The one exception: injury cases

One exception is worth stating, because the rest of this page reads as though paying yourself is the only route. It is not. If you were hurt in a crash or at work and a case is open, treatment can go ahead on a lien basis. We treat now and get paid from the settlement, rather than by you at the time.

That is not insurance, and we file no claim. It is a written agreement signed by you, your attorney and this practice. The routes are compared on paying for treatment, and the mechanics are on letter of protection and what a medical lien is.

The order that saves people money

• Find out whether you are a candidate first. Pre-tax dollars spent on a treatment that was never going to help you are still spent.
• Ask your administrator before you commit, and use the diagnosis rather than the brand name of the treatment.
• Ask what documentation they want, and get it before the appointment rather than after.
• Keep the receipt. Proving the expense is the account holder’s job, not the clinic’s.

The candidacy question comes first for a reason. The four things that decide it will tell you more about whether this is worth funding than any financing conversation will.

What people ask about paying for it

Can I submit a claim myself?

You can try, and it will almost certainly be denied as a non-covered service. Either way we give you an itemized receipt with the diagnosis and the service. That is the document an HSA or FSA administrator asks for. Paying for it.

Will you bill my insurance?

No. This is a self-pay practice. We file no claim and seek no authorization. You will know the cost before any blood is drawn. Ask us about your case.

Is PRP covered by Medicare?

No — Medicare does not cover it, and we do not bill. How we assess candidacy.

Why not just bill it as a joint injection?

Because that describes a different service. We will not do it. Coding, stated plainly.

Is there a cheaper option that actually works?

Sometimes yes, and we will say so. A supervised exercise program often has the best evidence of anything here. Prolotherapy.

What the evidence actually says

It is worth being concrete, because “not covered” gets heard as “not proven” and the two are unrelated.

Professional bodies do not issue consensus recommendations on experimental treatments. PRP for knee osteoarthritis now has them from more than one direction: a joint ESSKA–ICRS consensus and a European ESSKA–ORBIT consensus on injectable orthobiologics, both in 2024, an AAPM&R guidance statement, and an AAOS Technology Overview devoted to it. Regenerative treatments for chronic pain have their own evidence-based clinical practice guidelines.

The society this practice belongs to has gone further. In 2025 the American Society of Interventional Pain Physicians published a 119-page evidence-based guideline for regenerative therapies in chronic low back pain — 35 authors, 19 recommendations, every one carried at 100% agreement, graded with the GRADE method. Its recommendations for intradiscal and epidural PRP rest on Level III evidence and are issued as moderate consensus recommendations; facet and sacroiliac applications are graded lower. Societies do not spend three years writing practice guidelines for treatments they consider experimental.

That same guideline is candid about what is missing — it names the scarcity of large high-quality trials as its principal limitation, and it tells clinicians to inform patients that these treatments are not covered by commercial insurance. The people who wrote the guideline describe the obstacle exactly the way this page does.

Underneath the guidelines sit meta-analyses of randomized trials rather than case series. A 2025 analysis in the American Journal of Sports Medicine concluded the improvement in knee osteoarthritis is clinically significant, not merely statistically detectable. Separate meta-analyses of randomized trials favor PRP over hyaluronic acid in the knee, over corticosteroid for long-term function in lateral epicondylitis, and over placebo in tendinopathy.

None of that makes PRP right for you, and this practice will tell you when it is a poor bet. It does mean the treatment is established medical practice with a real literature behind it, and the word your plan chose is a budgeting word rather than a scientific one.

And where the record is thinner

It would be dishonest to imply the evidence is uniform, and it is not. It is indication-specific, and the grading moves target by target rather than treatment by treatment. In the 2025 ASIPP guideline the lumbar spine alone splits four ways: intradiscal platelet-rich plasma and bone marrow concentrate at Level III, Fair; epidural platelet-rich plasma at Level III, Fair; facet joint injection at Level IV, Limited; sacroiliac at Level IV, Limited. Four targets a few inches apart and four different evidentiary tiers.

The second limitation is that a great many published trials never describe what they injected in enough detail to reproduce it, so pooling them compares treatments that were never the same treatment — and almost none of them recorded the metabolic state of the patient receiving it, which is the variable this practice treats as decisive.

That is the honest shape of it: strongest and most consistent in the knee and in several tendinopathies, graded lower at some spinal targets, and dependent on a preparation and a patient that most trials never characterized. Which is the argument for a careful assessment rather than an argument from a headline — see why the trials disagree.

Follow the money, because it explains the classification

There is a version of this page that stops at “your insurer will not pay for it, sorry.” That version is useless. It treats a payer decision as though it fell out of the sky.

Here is the fuller accounting. We subsidize the crop that drives the disease, then we means-test the insulin. Refined carbohydrates and industrial seed oils are engineered into the cheapest calories on the shelf. Policy sets that price, not nature. And they land hardest in the neighborhoods with the fewest alternatives. Two decades later the same system pays for the metformin, the knee replacement and the disability claim, then calls the eighty-dollar preventive step unproven.

That is not a conspiracy. It is an incentive structure, and those do not need anyone’s bad intentions to do predictable damage. An insurer manages its own risk pool, one year at a time. Nobody in that arrangement answers for the twenty-year bill, so nobody prices it.

What that has to do with your tendon

Everything, and this is the part the coverage letter cannot say. The trials the payers lean on shut out people with diabetes, a higher BMI, inflammatory disease and more than one painful site. That is to say, they shut out the people the food system manufactured. Then a decision built on those trials is applied to exactly those people.

The result is a closed loop. The people most likely to have body-wide inflammation driving a failed repair are the people least represented in the evidence, and the most likely to be turned down. You are being quoted an average from a study that would not have let you in.

The people this lands on

Pain refugees. Patients passed from one specialty to the next, told their scans look unremarkable, and left with the quiet suggestion that the real problem is their willpower. They arrive carrying shame for a metabolic process nobody ever explained to them.

They are also the people for whom every remaining option is out of pocket. That is the real cost of the label, and it is worth naming rather than filing under “coverage.”

Where this actually sits with the FDA

Patients ask whether this is experimental, usually because of the wording in a denial letter. It is not. What a treatment is, and whether a plan pays for it, are two separate questions, and a denial letter is only ever answering the second.

• It is approved by the FDA for use in humans. The systems that prepare it are regulated medical devices with FDA clearance, and platelet-rich plasma is given under that framework. This is established medical practice. It is not a trial and not an experiment.
• The material is your own blood. Drawn from you, concentrated, returned to you in the same visit. There is no donor material and no drug.
• You are not enrolled in anything. No study, no placebo arm, no protocol. A physician assesses you and treats you.

So why will my plan not pay for it?

Because the language in that letter is payment language, not regulatory language. It means the plan decided the cost of funding this across its whole membership is not one it will carry. It is a budgeting call about what the plan buys, and it is made by people who are not examining you.

It does not say the procedure is unlawful, unproven for you, or experimental in the regulatory sense. Plans refuse plenty of lawful, well-established care, and they cover some things on weaker evidence than this.

What that means for you is simple. This is a self-pay practice. We do not bill insurance, and you will know the cost before any blood is drawn. What that means for you, including pre-tax accounts.

Common questions

Can I use my HSA for PRP?

Possibly. The tax test is whether it counts as medical care under section 213(d). That is a different question from whether your insurer covers it. Your plan administrator decides your case. Settle candidacy first.

Does a denial make it HSA-ineligible?

No. The two decisions are separate, and a bill nobody else paid is exactly the kind these accounts are built for. What the treatment actually is.

What about PRP for hair loss?

Cosmetic use is explicitly excluded from qualifying medical expenses, and it is not something this practice does. What we treat.

Will you write a letter of medical necessity?

Yes, describing the diagnosis and the clinical reasoning. We cannot make your plan accept it. Ask us.